157 related articles for article (PubMed ID: 32947841)
21. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
[TBL] [Abstract][Full Text] [Related]
22. Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014: Relevance of Surgical Cure in the Era of Modern Systemic Therapy.
Deutsch GB; Flaherty DC; Kirchoff DD; Bailey M; Vitug S; Foshag LJ; Faries MB; Bilchik AJ
JAMA Surg; 2017 Jul; 152(7):672-678. PubMed ID: 28384791
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
[TBL] [Abstract][Full Text] [Related]
24. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
Hendriks LEL; Bootsma G; Mourlanette J; Henon C; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Duchemann B; Cousin S; le Pechoux C; Botticella A; De Ruysscher D; Dingemans AC; Besse B
Eur J Cancer; 2019 Jul; 116():182-189. PubMed ID: 31203193
[TBL] [Abstract][Full Text] [Related]
25. Management of leptomeningeal metastases: Prognostic factors and associated outcomes.
Brower JV; Saha S; Rosenberg SA; Hullett CR; Ian Robins H
J Clin Neurosci; 2016 May; 27():130-7. PubMed ID: 26778048
[TBL] [Abstract][Full Text] [Related]
26. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
[TBL] [Abstract][Full Text] [Related]
27. Metastatic melanoma: prognostic factors and survival in patients with brain metastases.
Frinton E; Tong D; Tan J; Read G; Kumar V; Kennedy S; Lim C; Board RE
J Neurooncol; 2017 Dec; 135(3):507-512. PubMed ID: 28819707
[TBL] [Abstract][Full Text] [Related]
28. The changing paradigm of management in melanoma brain metastases.
Ladwa R; Atkinson V
Asia Pac J Clin Oncol; 2018 Dec; 14(6):453-458. PubMed ID: 29932306
[TBL] [Abstract][Full Text] [Related]
29. Changes in outcomes and factors associated with survival in melanoma patients with brain metastases.
Hasanov M; Milton DR; Davies AB; Sirmans E; Saberian C; Posada EL; Opusunju S; Gershenwald JE; Torres-Cabala CA; Burton EM; Colen RR; Huse JT; Glitza Oliva IC; Chung C; McAleer MF; McGovern SL; Yeboa DN; Kim BYS; Prabhu SS; McCutcheon IE; Weinberg JS; Lang FF; Tawbi HA; Li J; Haydu LE; Davies MA; Ferguson SD
Neuro Oncol; 2023 Jul; 25(7):1310-1320. PubMed ID: 36510640
[TBL] [Abstract][Full Text] [Related]
30. Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.
Tio M; Wang X; Carlino MS; Shivalingam B; Fogarty GB; Guminski AD; Lo S; Hong AM; Menzies AM; Long GV
Pigment Cell Melanoma Res; 2018 Jul; 31(4):509-515. PubMed ID: 29277979
[TBL] [Abstract][Full Text] [Related]
31. The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.
Rulli E; Legramandi L; Salvati L; Mandala M
Cancer; 2019 Nov; 125(21):3776-3789. PubMed ID: 31287564
[TBL] [Abstract][Full Text] [Related]
32. Leptomeningeal metastases arising from gynecological cancers.
Yano H; Nagao S; Yamaguchi S
Int J Clin Oncol; 2020 Feb; 25(2):391-395. PubMed ID: 31586282
[TBL] [Abstract][Full Text] [Related]
33. A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.
Ugurel S; Loquai C; Kähler K; Hassel J; Berking C; Zimmer L; Haubitz I; Satzger I; Müller-Brenne T; Mikhaimer NC; Becker JC; Kilian KJ; Schadendorf D; Heinzerling L; Kaatz M; Utikal J; Göppner D; Pföhler C; Pflugfelder A; Mössner R; Gutzmer R;
Ann Oncol; 2015 Mar; 26(3):573-82. PubMed ID: 25524477
[TBL] [Abstract][Full Text] [Related]
34. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis.
Petrelli F; Ardito R; Merelli B; Lonati V; Cabiddu M; Seghezzi S; Barni S; Ghidini A
Melanoma Res; 2019 Feb; 29(1):1-12. PubMed ID: 30308577
[TBL] [Abstract][Full Text] [Related]
35. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
36. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
Wu YL; Zhao Q; Deng L; Zhang Y; Zhou XJ; Li YY; Yu M; Zhou L; Zou BW; Lu Y; Liu YM
Lung Cancer; 2019 Jan; 127():1-5. PubMed ID: 30642536
[TBL] [Abstract][Full Text] [Related]
37. Survival in melanoma brain metastases in the era of novel systemic therapies.
Merola JP; Ocen J; Kumar S; Powell J; Hayhurst C
Neurooncol Adv; 2020; 2(1):vdaa144. PubMed ID: 33392503
[TBL] [Abstract][Full Text] [Related]
38. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
Long GV; Grob JJ; Nathan P; Ribas A; Robert C; Schadendorf D; Lane SR; Mak C; Legenne P; Flaherty KT; Davies MA
Lancet Oncol; 2016 Dec; 17(12):1743-1754. PubMed ID: 27864013
[TBL] [Abstract][Full Text] [Related]
39. [Melanoma brain metastases : Treatment options].
Rauschenberg R; Tabatabai G; Troost EG; Garzarolli M; Beissert S; Meier F
Hautarzt; 2016 Jul; 67(7):536-43. PubMed ID: 27206449
[TBL] [Abstract][Full Text] [Related]
40. Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer.
Turkaj A; Morelli AM; Vavalà T; Novello S
Front Oncol; 2018; 8():278. PubMed ID: 30140655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]